Vivozon Inc.
- Biotech or pharma, therapeutic R&D
Vivozon has been developing New Drug candidates using Multi-Target based innovative drug discovery since 2008 and mainly focused on Pain medication esp. Post-Operative Pain, Neuropathic Pain, Canacer Pain and other various pain management. Recently, Opiranserin was approved as New Drug from Korea in 2024 (brand, Unafra) for post surgery pain and which is now in Phase 3 in the US.
Also, VVZ-2471 for Neuropathic pain and Drug Addiction is now in Phase 2 study in Korea. VVZ-E2(3416) applicable for anti-Obesity, Parkinson's Disease and Alzheimer disease is in preclinical, and VVZ-N3 for Schizophrenia as a Best-in-Class having a remarkable advantage of Body Weight management is being closely discussed with domestic and overseas companies. ..
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}